Investor AB holds a concentrated book of 10 stocks worth $15.1B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). The SEC 13F shows only Investor AB's US-listed positions. Its main portfolio is mostly Stockholm-listed and does not appear in this book. This quarter they opened AstraZeneca PLC and trimmed Coherent Corp. Their largest long position is AstraZeneca PLC at 67% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/889232/holdings"
Use Arkolith to show INVESTOR AB's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | AstraZeneca PLC ORD | $10.2B | 51.59M | 67.3% | ▲New New position | |
| 2 | Nasdaq Inc COM | $4.9B | 58.38M | 32.6% | ▲+0.3% Added · +200K sh | |
| 3 | Mediwound Ltd SHS NEW | $14.0M | 872.1K | 0.1% | —Held | |
| 4 | Cellebrite Di Ltd ORDINARY SHARES | $758K | 55.0K | 0.0% | ▲New New position | |
| 5 | Coherent Corp COM | $715K | 3.0K | 0.0% | ▼−50% Reduced · −3K sh | |
| 6 | Kyivstar Group Ltd ORD SHS | $601K | 59.4K | 0.0% | ▲New New position | |
| 7 | Verizon Communications Inc COM | $567K | 11.3K | 0.0% | ▲New New position | |
| 8 | Corsair Gaming Inc COM | $553K | 99.7K | 0.0% | ▼−20% Reduced · −25K sh | |
| 9 | Whirlpool Corp COM | $253K | 4.7K | 0.0% | ▲+27% Added · +1K sh | |
| 10 | Biomarin Pharmaceutical Inc COM | $209K | 3.7K | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 10 | $15.1B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 12 | $5.7B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 12 | $5.2B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 13 | $5.2B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 13 | $4.4B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 8 | $4.5B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 7 | $4.3B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 6 | $3.5B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 10 | $3.7B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 10 | $3.4B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 9 | $2.8B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 9 | $2.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 7 | $3.2B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 5 | $3.6B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 7 | $3.3B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 5 | $3.0B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 8 | $3.5B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 7 | $4.1B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 4 | $3.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 3 | $3.4B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 2 | $2.9B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 3 | $2.6B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 7 | $2.4B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 4 | $2.3B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.